NCT02523430View on ClinicalTrials.gov

HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Nasopharyngeal Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Nasopharyngeal Carcinoma
Interventions
PROCEDURE

interventional therapy

nasopharyngeal carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）

Trial Locations (1)

510000

Central laboratory in Fuda cancer hospital, Guangzhou

All Listed Sponsors
lead

Fuda Cancer Hospital, Guangzhou

OTHER

NCT02523430 - HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter